Last update July 11, 2025
Limited compatibility
We do not have alternatives for Ropinirole Hydrochloride.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Ropinirole Hydrochloride in other languages or writings:
Ropinirole Hydrochloride belongs to this group or family:
Main tradenames from several countries containing Ropinirole Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 45 - 55 | % |
Molecular weight | 297 | daltons |
Protein Binding | 40 | % |
VD | 7.5 | l/Kg |
pKa | 12.27 | - |
Tmax | 1 - 2 | hours |
T½ | 6 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Non-ergoline D2/D3 dopamine agonist. Indicated for Parkinson's disease and restless legs syndrome (one dose at night). Oral administration in three daily doses.
At the date of the last update, we found no data on its excretion in breast milk.
Its pharmacokinetic data do not allow for easy prediction of its possible passage into breast milk, as while its low protein binding would not prevent this, its very large volume of distribution makes it difficult.
Its low bioavailability, which decreases further when taken with food, suggests that little passes into the infant's plasma, except in the neonatal period and in cases of prematurity, when intestinal absorption may be increased.
Its side effects are neither frequent nor serious.
It decreases prolactin levels (de Mey 1990, Acton 1989), which may affect milk production during the first weeks after birth. In fact, it can be used as a substitute for ergot derivatives in the treatment of idiopathic hyperprolactinemia or secondary to microprolactinoma. (Heneghan 2024)
Plasma levels increase significantly when taken with ciprofloxacin. (Kaye 2000)
If taken during breastfeeding, it is prudent to avoid the first 15 to 20 days and monitor milk production and the appearance of nausea, constipation, sweating, drowsiness or irritability in the infant. Waiting 6 hours after taking the medication minimises its possible passage into milk.